These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9421870)

  • 41. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
    Jung SH
    Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spatial Two-stage Designs for Phase II Clinical Trials.
    Kim S; Wong WK
    Comput Stat Data Anal; 2022 May; 169():. PubMed ID: 35058669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
    Berchialla P; Zohar S; Baldi I
    Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal two-stage designs for exploratory basket trials.
    Zhou H; Liu F; Wu C; Rubin EH; Giranda VL; Chen C
    Contemp Clin Trials; 2019 Oct; 85():105807. PubMed ID: 31260789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.
    Mander AP; Wason JM; Sweeting MJ; Thompson SG
    Pharm Stat; 2012; 11(2):91-6. PubMed ID: 22232071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.
    Ji L; Whangbo J; Levine JE; Alonzo TA
    Contemp Clin Trials; 2022 Sep; 120():106849. PubMed ID: 35868503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.
    Zhao L; Taylor JM; Schuetze SM
    Stat Med; 2012 Jul; 31(17):1804-20. PubMed ID: 22359354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design of Phase II cancer trials evaluating survival probabilities.
    Case LD; Morgan TM
    BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.
    Kwak M; Jung SH
    Stat Med; 2014 May; 33(12):2004-16. PubMed ID: 24338995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.
    Mander AP; Thompson SG
    Contemp Clin Trials; 2010 Nov; 31(6):572-8. PubMed ID: 20678585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An optimal two-stage phase II design utilizing complete and partial response information separately.
    Panageas KS; Smith A; Gönen M; Chapman PB
    Control Clin Trials; 2002 Aug; 23(4):367-79. PubMed ID: 12161080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal two-stage design of single arm Phase II clinical trials based on median event time test.
    Park Y
    PLoS One; 2021; 16(2):e0246448. PubMed ID: 33556130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Rescue Strategy for Handling Unevaluable Patients in Simon's Two Stage Design.
    Belin L; Broët P; De Rycke Y
    PLoS One; 2015; 10(9):e0137586. PubMed ID: 26368810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.
    Wason JM; Mander AP; Eisen TG
    Eur J Cancer; 2011 May; 47(7):983-9. PubMed ID: 21239164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flexible designs for phase II comparative clinical trials involving two response variables.
    Bersimis S; Sachlas A; Papaioannou T
    Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
    Kunzmann K; Kieser M
    Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.